Table 1 Patient characteristics and outcome of unmatched ALI patients
No Heparin n = 559 | Heparin n = 164 | pvalue | |
|---|---|---|---|
Age, mean (SD) | 59 (17) | 63 (14) | 0.003 |
Male,% (n) | 70 (389) | 63 (103) | 0.10 |
APACHE II score, mean (SD) | 17.8 (6.9) | 19.8 (6.5) | 0.001 |
Medical patients,% (n) | 60 (334) | 71 (117) | 0.007 |
Surgery elective,% (n) | 23 (128) | 19 (31) | 0.28 |
Surgery emergency,% (n) | 17 (97) | 7 (16) | 0.02 |
Medical condition | |||
Multiple Trauma,% (n) | 8 (43) | 2 (3) | 0.007 |
Sepsis,% (n) | 21 (115) | 18 (29) | 0.42 |
Diabetes,% (n) | 14 (81) | 16 (27) | 0.53 |
Liver Failure,% (n) | 3 (14) | 2 (4) | 0.96 |
Hematological malignancy,% (n) | 6 (35) | 2 (3) | 0.03 |
Aspiration,% (n) | 5 (26) | 4 (6) | 0.59 |
Pancreatitis,% (n) | 2 (12) | 2 (4) | 0.82 |
Pneumonia,% (n) | 23 (129) | 10 (17) | < 0.001 |
COPD | 11 (62) | 14 (23) | 0.31 |
Auto immune disease,% (n) | 6 (34) | 9 (15) | 0.17 |
Previous Myocardial infarction,% (n) | 13 (72) | 40 (66) | < 0.001 |
Immune Compromised,% (n) | 11 (61) | 6 (10) | 0.07 |
Massive Transfusion,% (n) | 14 (78) | 12 (19) | 0.43 |
Life support measures | |||
Respiratory failure (MV) ,% (n) | 93 (519) | 95 (156) | 0.42 |
Cardiovascular failure (MI) ,% (n) | 13 (72) | 40 (66) | <0.001 |
Co interventions | |||
Activated Protein C,% (n) | 4 (24) | 1 (1) | 0.02 |
Stress dose steroids,% (n) | 42 (233) | 46 (76) | 0.29 |
Protective mechanical ventilation (<8 ml/kg) ,% (n) | 54 (304) | 55 (91) | 0.29 |
Restrictive fluid strategy (net fluid balance first 7 days ≤ 0 ml) ,% (n) | 36 (203) | 35 (58) | 0.82 |
Outcome | |||
28 days mortality,% (n) | 24 (134) | 30 (50) | 0.09 |
90 days mortality,% (n) | 32 (181) | 39 (64) | 0.11 |
ICU-stay, median (IQR) | 7 (4–13) | 7 (4–13) | 0.59 |
Hospital-stay, median (IQR) | 20 (11–38) | 18 (8–37) | 0.13 |